Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

OTCPK:ARLZQ - Post Discussion

View:
Post by Floridas2000 on Jan 30, 2017 2:27pm

Zack's Report

Here is their latest report.     Zack report
Comment by mjh9413 on Jan 30, 2017 3:36pm
Thanks, but gee, they are very poor numbers and don't justify $US11 target even at 2020. The Q4 numbers, well, no surprise Sp is dropping. Yuk eom
Comment by Bigboyone on Feb 03, 2017 10:50am
Got a Chance to go over the Zack's number's. I see they are very conservative, and to MJH9413 post, my reply..they did not include Sales (ESTIMATE) in EU or other possible sales Area's (Japan /Middle east, etc)going forward in 2017 or 2018. As frustrating as it is, and I have been involved with other piece of S@*T stocks before, this is not one of those, sadly tho, MM slow and very ...more  
Comment by LG2264 on Feb 09, 2017 4:08pm
Does anyone recall that in 2018 our proceeds for Vimovo are supposed to almost double. I just seem to recall that ,back when Posen and Tribute was going thru the merging process. Of course I may just be wishful thinking or hallucinating. If it is true I don't see those numbers in the report.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities